PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer and Lymphoma?

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
PROACT will establish the effectiveness of the angiotensin-converting enzyme inhibitor (ACEI) enalapril maleate (enalapril) in preventing cardiotoxicity in patients with breast cancer and non-Hodgkin lymphoma undergoing adjuvant epirubicin-based chemotherapy.
Epistemonikos ID: 80bbddd09365cc39b11bf8418bf812c188afa8e9
First added on: May 21, 2024